Chester County News and Community Website
BERWYN, PA — Panavance Therapeutics Inc. has announced groundbreaking findings this week, demonstrating the potential of their investigational drug, misetionamide (GP-2250), to tackle various forms of cancer by directly inhibiting …
Panavance Therapeutics Unveils Promising Data on Misetionamide’s Dual Cancer Targeting Mechanism Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has unveiled encouraging preliminary data from the Phase 1 portion of its OCU410 ArMaDa clinical trial, aimed at treating geographic atrophy (GA) secondary …
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) recently presented encouraging clinical data for its investigational therapy, CABA-201, at the American College of Rheumatology (ACR) Convergence 2024 in Washington, D.C. …
Cabaletta Bio Unveils Promising Data on CABA-201 at ACR Convergence 2024 Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) recently presented encouraging data from its studies on nomlabofusp at the International Congress for Ataxia Research in London. The data, derived …
Larimar Therapeutics Shares Promising Data on Nomlabofusp at Ataxia Research Congress Read More
PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled encouraging new immunology data for its lead product candidate, INO-3107, which is designed to treat recurrent respiratory papillomatosis (RRP), a condition caused …
INOVIO Announces Promising Immunology Data for INO-3107 in RRP Treatment Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has announced promising new data from its IM-PROVE I Phase 2a clinical trial, suggesting significant advancements in treatment for chronic hepatitis B …
Arbutus Biopharma’s Clinical Trial Shows Promise for Hepatitis B Treatment Read More WARMINSTER, PA and OXFORD, United Kingdom — Arbutus Biopharma Corporation and Barinthus Biotherapeutics recently unveiled encouraging preliminary results from their Phase 2a IM-PROVE II clinical trial at the American Association …
Promising New Data from Hepatitis B Trial by Arbutus and Barinthus Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced its financial results for the third quarter ending September 30, 2024, alongside significant progress in its Alzheimer’s treatment pipeline.
Annovis Bio Advances Alzheimer’s Treatment with Phase 3 Trials and Financial Updates Read More
WAYNE, PA — Palvella Therapeutics, Inc. has announced the commencement of dosing in its Phase 3 SELVA trial, aimed at evaluating QTORIN™ 3.9% rapamycin anhydrous gel for treating microcystic lymphatic malformations …
Palvella Therapeutics Begins Phase 3 Trial for Microcystic Lymphatic Malformations Treatment Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) announced the swift completion of participant enrollment in its Launch-HTN trial, a critical component of its pivotal program investigating lorundrostat for the …
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Pivotal Hypertension Trial Read More